APAC Hospital Priorities – China Pharma Perspective

Stephen Sunderland

title slide

table of contents

hospital survey respondent mix

private vs public hospital mix

budget outlook for public hospitals

restrictions on sales rep access

hospital spending priorities

innovative drug access

barriers to NRDL drugs

spending through VBP

changes in prescription behavior

cutting back on commercial investment

change in prescription from hospitals

focus areas

value of digital health solutions

top concerns for digital health adoption

adoption of digital tools

disclaimer

thank you

Related Insights

Executive Insights

Life Sciences & Pharma

From Discovery to Launch: Building Next-Generation Investment Governance for Biotech

January 13, 2026

Video / Webinar

Life Sciences & Pharma

Pharma Growth in China: Key Partnerships and Global Opportunities

November 14, 2025

Executive Insights

Life Sciences & Pharma

Indonesia’s Retail Pharmacy Landscape: Why Global Investors Should Take a Closer Look

October 16, 2025

Video / Webinar

Life Sciences & Pharma

China’s Innovation Momentum: Powered by Life Science Research Tools and Enablers

October 14, 2025

Executive Insights

Life Sciences & Pharma

Is Biopharma Doing Enough to Advance Novel Targets?

May 15, 2025

Executive Insights

Life Sciences & Pharma

Quantum Computing in Biopharma: Future Prospects and Strategic Insights

May 1, 2025